PYC Physiomics Plc

TIDMPYC

Physiomics PLC

02 July 2018

Physiomics plc

("Physiomics") or ("the Company")

Physiomics expands technical team

Physiomics is pleased to announce that Dr Claire Villette has joined its technical team as a Biosimulation scientist.

Claire is a biomedical computational scientist with 6 years' experience in multiscale modelling of biological tissue growth. She completed her PhD in Computational Biomechanics at Imperial College London where she was awarded an EPSRC Doctoral Prize fellowship to investigate new digital design optimisation techniques for tissue engineering scaffolds using machine learning algorithms. Claire has also completed a secondment at an Imperial College spin-out where she developed a commercial software application for tailored tissue engineering.

Jim Millen commented "As Physiomics continues to expand its client base we need talented young scientists to help us deliver the high-quality work our clients have become used to. I'm confident that Claire will be a great addition to the team".

For further information please contact:

Physiomics Plc

Dr Jim Millen

+44 (0)1865 784980

WH Ireland Limited (nomad)

Katy Mitchell/James Sinclair-Ford

+44 (0) 161 832 2174

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

About Physiomics plc

Physiomics plc (AIM: PYC) is a solutions provider to the R&D-based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by over 60 projects, involving over 25 targets and 60 drugs.

Based in Oxford, UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics' senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAKMGGNZZFGRZM

(END) Dow Jones Newswires

July 02, 2018 08:57 ET (12:57 GMT)

Physiomics (LSE:PYC)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024

Physiomics (LSE:PYC)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024